Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PC-0127
- Development stage
- Preclinical
- Lead developer
- Changtai Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PC-0127 is an investigational small molecule drug candidate being developed by Changtai Pharmaceutical (also known as PharmaMax Corp) for the treatment of idiopathic pulmonary fibrosis (IPF). Formulated as an oral capsule, it is part of the company's respiratory pipeline, which focuses on addressing unmet needs in chronic lung diseases. While the specific biological target and mechanism of action for PC-0127 have not been publicly disclosed, it is being developed as a potential oral therapy to mitigate the progressive lung scarring associated with IPF. It is positioned in the developer's portfolio alongside PC-0109, an inhaled liposomal formulation also targeting idiopathic pulmonary fibrosis.
Beyond the preview
Go deeper on PC-0127.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PC-0127.